Compare Ginkgo Bioworks Holdings Inc (DNA) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Standard Lithium Ltd — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.7 (market cap $763.64M), while Standard Lithium Ltd trades at $1.61 (market cap $398.07M). The key difference: Ginkgo Bioworks Holdings Inc is the larger of the two by market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Standard Lithium Ltd for 23 Days on average.
| DNA | SLI | |
|---|---|---|
Market Cap | $763.64M | $398.07M |
Volume | 3,204,177 | 1,564,155 |
Sector | Health | Basic Materials |
52-Week High | $15.83 | $5.65 |
52-Week Low | $5.48 | $1.61 |
Typical Hold Time | 7 Days | 23 Days |
Enterprise Value | $865.59M | $260.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
Standard Lithium (SLI) trades at $1.65, down 4.62% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE of -15.55% and ROA of -14.17%, though recent quarterly EPS beat expectations. Positive developments include progress toward a 2026 final investment decision for the Arkansas lithium project and expanded offtake agreements. Cash flow remains supported by financing activities despite negative operational cash flow.
The investment case hinges on successful project execution and lithium market dynamics. Analysts are unanimously bullish with a $3.83 price target, representing significant upside. Key risks include execution delays, negative cash flow, and commodity price volatility. The stock offers high-risk, high-reward exposure to North American lithium production growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
